Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Chronic Pouchitis
NCT04580277Phase 2Terminated
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in pouchitis, sponsored by Cedars-Sinai Medical Center. Primary endpoint: Number of Participants With Clinical Response/Remission at 8 weeks. Started Jan 2021; status: terminated.
02
Drugs
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT04580277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580277.